Research published in the journal Radiology shows that the combination of transparency-based lesion detection, volumetric density and quantitative texture analysis enables improved breast cancer risk prediction
ScreenPoint Medical today announced the acquisition of Biomediq A/S, a research-based company focused on the discovery, development and implementation of quantitative imaging biomarkers. After a decade of close collaboration as separate entities on image-based risk assessment, this deal aims to bring breast cancer risk assessment capabilities to ScreenPoint’s industry-leading breast AI, Transpara.
Biomediq’s breast cancer risk analysis technology enables automatic, computer-assisted evaluation of 2D and 3D mammograms to analyze future breast cancer risk. It is based on a mammographic texture risk biomarker that detects tissue heterogeneity, often referred to as mammographic texture, which is associated with both short- and long-term breast cancer risk.
The potential of Transpara’s detection and density tools combined with Biomediq’s texture model was highlighted in a 2023 publication, „Assessing Breast Cancer Risk by Combining AI for Lesion Detection and Mammographic Texture“. In this one Radiologypublication, Lauritzen et al. showed that the combination of Transpara-based lesion detection, volumetric density measurement and quantitative texture analysis leads to improved risk prediction. Additionally, further imaging for women at highest risk of transpara could have doubled early cancer detection by detecting interval cancer before subsequent visits compared to traditional screening. The first author of this work, Dr. Andreas D. Lauritzen, will join the ScreenPoint team to accelerate the development of Transpara’s risk capabilities.
Transpara is the most clinically validated breast AI on the market, providing radiologists with a “second set of eyes” to detect cancers earlier and reduce recall rates. ScreenPoint recently launched Transpara 2.1, an updated algorithm based on additional training and insights collected from notable users around the world, Transpara 2.1 comes with options for automatic breast density measurement (BIRADS and volumetric) and a robust time comparison option Compatible with the unmatched temporal comparison capability, which allows suspicious areas of a current study to be analyzed with up to three previous studies over a six-year period, as well as the Temporal Comparison and Density are CE marked and FDA approved.
“Risk-stratified screening has long been proposed to optimize patient care and make better use of resources,” said Professor Nico Karssemeijer, co-founder and chief scientific officer of ScreenPoint Medical. “We are pleased to add Biomediq technology to risk analysis, to expand Transpara’s capabilities and improve performance in mammography-based breast cancer risk assessment. This is a critical step towards accurate and consistent breast cancer detection and treatment for all women.
According to Biomediq co-founder Professor Mads Nielsen, “Our long-standing collaboration and close relationship with the ScreenPoint team is based on our shared vision of enabling better screening for women.” Bringing together our technologies to support radiology workflows and care Women is an exciting result of this intensive and complementary collaboration. Prof. Nielsen will continue to advise the expanded ScreenPoint team.
With more than 35 peer-reviewed publications, Transpara is the only breast AI algorithm that has been evaluated multiple times in large, real-world screening populations (including UCLA, Capital Region of Denmark, Lund University in Sweden, Norwegian Cancer Registry, Reina Sofia Hospital Córdoba). The study shows that Transpara can detect up to 45% of interval cancers earlier, while reducing workload and optimizing workflow.
Information about Biomediq
Biomediq is a research-based company focused on the discovery, development and introduction of quantitative imaging biomarkers for improved breast cancer prevention, diagnosis, prognosis and monitoring.
About ScreenPoint Medical
ScreenPoint Medical translates cutting-edge machine learning research into radiologist-accessible technology to Screeningablaufdie Decision certainty and the Risk assessment for breast cancer. Transpara is trusted by radiologists around the world as it was developed by experts in machine learning and imaging analysis and updated with feedback from globally recognized breast imaging experts. All evidence can be found on: https://screenpoint-medical.com/published-evidence/peer-reviewed-publications
Logo – https://mma.prnewswire.com/media/1582198/ScreenPoint_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/screenpoint-medical-erwirbt-biomediq-as-um-die-moglichkeiten-der-brustkrebsrisikobewertung-zu-erweitern-302346135.html